Lara Barazzuol

Associate Professor

University Medical Center Groningen
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Year:

2026

Introduction. Pseudoprogression (PsP) after proton therapy (PT) can mimic tumour progression and may cause neurological morbidity. We characterised PsP incidence, risk factors, spatial distribution and longitudinal dynamics in adults with IDH-mutated grade 2–3 glioma treated with PT.Methods. Patients treated between 2018–2022 were included. Post-PT MRIs were centrally reviewed for contrast-enhancing PsP. We estimated actuarial incidence (Kaplan–Meier), evaluated clinical risk factors using Cox regression, and analysed lesion location and volumetric behaviour over time.Results. PsP occurred in 33/137 (24.1%) patients; 8 (5.8%) developed symptomatic PsP (CTCAE grade ≥2). Mean time to first PsP was 18.1 months, and 2-year actuarial incidence was 18.1% overall (14.7% in grade 2 and 29.0% in grade 3 glioma). Independent risk factors were age >50 years (Hazard Ratio (HR) 2.5), Fazekas grade ≥2 on pre-PT MRI (HR 3.6), and treatment in 2021 (HR 3.2).In total, 115 PsP lesions were identified: 53 (46.1%) in the periventricular space (PVS) and 5 (4.3%) in the optic pathway. All symptomatic lesions involved the PVS and/or optic pathway. Symptomatic PVS-PsP showed multifocality, earlier onset (mean 14 months), faster growth (>0.5 cc/month) and larger cumulative volumes (>1.75 cc).Conclusion. Clinically consequential PsP after PT clustered in the PVS and optic pathway. Baseline clinical factors and simple volumetric dynamics may support risk-adapted surveillance and earlier multidisciplinary review, but proposed volumetric triggers require external validation.

Year:

2026

The goal of radiotherapy in cancer treatment is to maximize DNA damage in tumors while minimizing harm to surrounding healthy tissues, especially to stem and progenitor cells essential for tissue regeneration and organ function. Here, we investigated the molecular responses to photon and proton irradiation, two key modalities in head and neck cancer treatment. Multiomics and in vitro analyses revealed that both photon and proton irradiation of mouse salivary gland organoids induced similar early responses, including DNA damage, micronuclei formation, increased amounts of the cytosolic DNA sensor cGAS, and type I interferon (IFN-I) signaling. In addition, both types of radiation induced comparable increases in the release of mitochondrial DNA (mtDNA) into the cytoplasm and stimulated the production of ZBP1, a cytosolic nucleic acid sensor involved in mtDNA recognition. However, proton irradiation resulted in a more pronounced loss of heterochromatin regulators and derepression of transposable elements at later times after irradiation, which was accompanied by increased accumulation of intracellular double-stranded RNA (dsRNA) and an enhanced RIG-I–mediated IFN-I response. Genetic and pharmacological modulation demonstrated its critical role for IFN-I signaling in enhancing salivary gland stem and progenitor cell activity after irradiation in vitro and in vivo. Our findings reveal more pronounced molecular changes after proton irradiation as compared with photon irradiation and uncover a proregenerative role of IFN-I signaling in the salivary gland, suggesting this pathway as a promising therapeutic target to mitigate radiation-induced side effects.

Year:

2025

Year:

2025

Year:

2024

Progressive neurocognitive dysfunction is the leading cause of a reduced quality of life in patients with primary brain tumors. Understanding how the human brain responds to cancer and its treatment is essential to improve the associated cognitive sequelae. In this study, we performed integrated transcriptomic and tissue analysis on postmortem normal‐appearing non‐tumor brain tissue from glioblastoma (GBM) patients that had received cancer treatments, region‐matched brain tissue from unaffected control individuals and Alzheimer's disease (AD) patients. We show that normal‐appearing non‐tumor brain regions of patients with GBM display hallmarks of accelerated aging, in particular mitochondrial dysfunction, inflammation, and proteostasis deregulation. The extent and spatial pattern of this response decreased with distance from the tumor. Gene set enrichment analyses and a direct comparative analysis with an independent cohort of brain tissue samples from AD patients revealed a significant overlap in differentially expressed genes and a similar biological aging trajectory. Additionally, these responses were validated at the protein level showing the presence of increased lysosomal lipofuscin, phosphorylated microtubule‐associated protein Tau, and oxidative DNA damage in normal‐appearing brain areas of GBM patients. Overall, our data show that the brain of GBM patients undergoes accelerated aging and shared AD‐like features, providing the basis for novel or repurposed therapeutic targets for managing brain tumor‐related side effects.

Year:

2024

Radiotherapy is a mainstay in cancer treatment, aiming to maximize DNA damage in tumors while minimizing harm to surrounding healthy tissues. However, the collateral damage to normal tissues, especially stem/progenitor cells essential for tissue regeneration and organ function, remains a significant challenge. Here, we investigate the molecular responses to photon and proton irradiation, two key modalities in head and neck cancer treatment, using organoids. Multiomics analysis reveals a stronger double-stranded RNA (dsRNA)-induced type I interferon (IFN-I) response following proton irradiation, driven by loss of heterochromatin regulators and derepression of transposable elements (TEs). This response, mediated by the cytoplasmic sensor RIG-I, enhances the inflammatory signaling initiated by the canonical dsDNA sensors cGAS and ZBP1. Genetic and pharmacological modulation of IFN-I signaling in vitro and in vivo demonstrates its critical role in enhancing stem/progenitor cell activity post-irradiation. Our findings reveal a pro-regenerative role of TE derepression-mediated IFN-I response suggesting this pathway as a promising therapeutic target to mitigate radiation-induced side effects. Teaser Transposable element-mediated type I interferon signaling enhances stem/progenitor cell activity after irradiation.

Year:

2024

Collaborators (13)

Abel Soto-Gamez

Scientific Researcher

University Medical Center Groningen

NETHERLANDS
View details

Rob J.M. Groen

Professor in Clinical Neurosurgery

University Medical Center Groningen

NETHERLANDS
View details

Marcel van Vugt

Principle Investigator/Adjunct Professor

University of Groningen

NETHERLANDS
View details

Marco Demaria

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Dirk Wagenaar

Medical Physicist

University Medical Center Groningen

NETHERLANDS
View details

Robert P Coppes

Scientific Staff

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Roland Chiu

Scientific Staff, Other Scientific Education Staff, Docent

University of Groningen

NETHERLANDS
View details

Dik C. van Gent

Associate professor

Erasmus University Rotterdam

NETHERLANDS
View details

Bart J. L. Eggen

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Luiza Reali Nazario

University Medical Center Groningen

NETHERLANDS
View details

Johannes A. Langendijk

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Steven Bergink

Scientific Staff, Other Scientific Education Staff, Docent

University of Groningen

NETHERLANDS
View details

Marc-Jan van Goethem

Deputy head of cyclotron facility

University Medical Center Groningen

NETHERLANDS
View details